Castle Biosciences, Inc. splits its revenue into 3 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Dermatologic at $216.4 million, 63% of the total.
USD in millions. The percent under a figure is the change from the year before.
| Line |
FY 2026
Sep 30, 2026
|
FY 2025
Dec 31, 2025
|
FY 2024
Dec 31, 2024
|
FY 2023
Dec 31, 2023
|
FY 2022
Dec 31, 2022
|
FY 2021
Dec 31, 2021
|
FY 2020
Dec 31, 2020
|
FY 2019
Dec 31, 2019
|
|---|---|---|---|---|---|---|---|---|
| Revenue |
377
|
344
|
332
|
220
|
137
|
94
|
63
|
52
|
| Dermatologic |
186
-19.6%
share 49.4%
|
216
-15.8%
share 62.9%
|
257
+40.1%
share 77.4%
|
183
+46.9%
share 83.4%
|
125
+45.5%
share 91.1%
|
86
+48.8%
share 91.1%
|
58
share 92.0%
|
—
|
| Non Dermatologic |
191
+70.4%
share 50.6%
|
128
+70.3%
share 37.1%
|
75
+106.2%
share 22.6%
|
36
+197.7%
share 16.6%
|
12
share 8.9%
|
—
|
—
|
—
|
| Other services |
—
|
—
|
—
|
—
|
—
|
8
+66.5%
share 8.9%
|
5
share 8.0%
|
—
|
How these figures are calculated
Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CSTL (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Friendswood, TX
- SEC filer status
- Accelerated filer
- SEC CIK
- 1447362
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- Caris Life Sciences, Inc. CAI
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
Source: SEC EDGAR filings. This is company-reported data, not investment advice.